Board Change • May 14
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. Member of Scientific Advisory Committee Ralph Weichselbaum is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • May 01
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $11 million in funding Shuttle Pharmaceuticals Holdings, Inc. announced that entered into a securities purchase agreement with certain accredited investors in a private placement offering of 2,200 shares of newly designated Series B-2 Convertible Preferred Stock at a price of $5000 and common warrants for gross proceeds of $11,000,000 on April 30, 2026. Upon subsequent receipt of Shuttle stockholder approval, the shares of Series B-2 Convertible Preferred Stock will be automatically convertible, at a conversion price of $1.03 (subject to adjustment), into an aggregate of approximately 9,708,738 shares of Company Common Stock, subject to customary beneficial ownership limitations. The Common Warrants have an exercise price of $1.03 and a 3-year term. The Series B-2 Convertible Preferred Stock and the Common Warrants issued in the Offering will not be exercisable or convertible until stockholder approval is obtained. Duyuru • Apr 13
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 21, 2026 Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 21, 2026. Duyuru • Feb 11
Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3.500001 million. Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3.500001 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,229,300
Price\Range: $1.57
Discount Per Security: $0.0628
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 2,229,300 New Risk • Dec 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 45% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.32m market cap). Duyuru • Nov 29
Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes, Effective November 21, 2025 On November 21, 2025, Timothy Lorber resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc., effective November 21, 2025. In connection with Mr. Lorber’s resignation, Mr. Lorber and the Company entered into a Separation Agreement and Mutual Release (the “Agreement”). Pursuant to the Agreement, Mr. Lorber will continue to provide part-time services at 50% of his base salary through December 4, 2025, to assist with matters related to the transition of his job duties, and thereafter shall remain available for reasonable consultation and inquiries through February 8, 2026. Effective November 21, 2025, Christopher Cooper, who currently serves as Interim Chief Executive Officer, assumed the role of Chief Financial Officer (Principal Financial Officer). Mr. Cooper will serve in this capacity while the Company conducts a search for a permanent Chief Financial Officer. Duyuru • Nov 18
Shuttle Pharmaceuticals Regains Nasdaq Compliance Shuttle Pharmaceuticals Holdings, Inc. reported stockholders’ equity of $1,394,161 in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, and, as a result, was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market (“Nasdaq”) to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholders’ Equity Requirement”). The Company believes that, as of the date of this Current Report on Form 8-K (this “Form 8-K”), it has regained compliance with the Stockholders’ Equity Requirement based upon the Company’s private placement consummated on November 4, 2025, pursuant to which the Company raised aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and offering expenses payable by the Company. The Nasdaq Listing Qualifications staff will continue to monitor the Company’s ongoing compliance with the Stockholders’ Equity Requirement and, if at the time of the Company’s next periodic report the Company does not evidence compliance with Listing Rule 5550(b)(1), the Company may be subject to delisting. Board Change • Sep 24
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Committee Ralph Weichselbaum is the most experienced director on the board, commencing their role in 2013. Independent Chairman of the Board George Scorsis was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • Jun 25
Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4.249998 million in funding from Lytham Partners, LLC On June 24, 2025, the Shuttle Pharmaceuticals Holdings, Inc. closed the transaction by issuing 21,924 shares at an issue price of $3.60 for the proceeds of $78,926.4 and 1,158,953 pre funded warrant at an issue price of $3.599 for the proceeds of $4,171,071.847 aggregate proceeds of $4,249,998.247. The transaction involves participation of Lytham Partners, LLC as a new investor. Company paid WestPark a fee of 4% of the gross proceeds received in the offering. Duyuru • Jun 21
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $4.251157 million in funding Shuttle Pharmaceuticals Holdings, Inc. announces that it entered into a securities purchase agreement to issue 1,180,877 shares of common stock at a price of 43.60 per share for gross proceeds of $4,251,157.2 on June 20, 2025. The offering is expected to close on or about June 23, 2025. New Risk • Jun 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.6m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 50% per year over the past 5 years. Shareholders have been substantially diluted in the past year (422% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.45m market cap). Duyuru • Jun 05
Shuttle Pharmaceuticals Holdings, Inc. Appoints George Scorsis as Chairman of the Board of Directors Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Health Corp., a leading Canadian cannabis distributor. From July 2017 to February 2019, Mr. Scorsis served as the Chief Executive Officer and Director of Liberty Health Sciences. From January 2015 to April 2018, Mr. Scorsis has served as Chairman of the Board of Directors of SOL Global Investments Corp. (formerly known as Scythian Biosciences Corp.) Mr. Scorsis also currently serves as the Chairman of Entourage Health Corp. (since February 2019) and Chairman of AWAKN Life Sciences (since January 2017), both of which are publicly traded on the TSX Venture Exchange and NEO Exchange. New Risk • May 10
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$8.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.6m free cash flow). Earnings have declined by 50% per year over the past 5 years. Shareholders have been substantially diluted in the past year (198% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.69m market cap). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Duyuru • Apr 11
Shuttle Pharmaceuticals Holdings, Inc. Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer Shuttle Pharmaceuticals Holdings, Inc. announced the filing of a key provisional patent application with the United States Patent and Trademark Office (USPTO) entitled "PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy." The filing is yet another critical advancement within the Company's Diagnostic subsidiary which aims to develop highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and for targeted therapy delivery using radio labelled PSMA ligands. The filing comes through Shuttle Pharma's collaboration with internationally renowned medicinal chemist, Dr. Alan Kozikowski. Dr. Kozikowski's original medicinal chemistry research performed in collaboration with Professor Joseph Neale and conducted at Georgetown University Medical Center were a component in the creation of both Pylarify and Pluvicto. This is the second patent application covering intellectual property that was discovered as part of that project. The concept of targeting cellular antigens using antibody-drug-conjugates (ADCs) has been an active and promising area of research over the past decade. Since the PSMA targeting ligands are much smaller in size, and offer potential advantages for more efficient drug delivery, at least for prostate cancer treatment, this may offer a promising avenue of research. Current focus is on both, the PSMA-B ligand, as well as the PC-Rad test for predicting outcomes following radiation therapy for localized prostate cancer. There are currently no available tests on the market that are predictive of success for a specific treatment. "I believe a significant opportunity exists for PSMA ligands for prostate cancer diagnosis and treatment," said Anatoly Dritschilo, MD, Shuttle Pharma's Chairman and Chief Scientific Officer. "The Shuttle Pharma scientists have collaborated with Dr. Kozikowski on discovery projects for radiation sensitizing drugs and have recently focused on discovery of novel PSMA ligands with the intent of targeting prostate cancer cells with the intent of targeting prostate Cancer cells preferentially to the effects of radiation and chemotherapeutic agents. The company look forward to the continued advancement of Shuttle Diagnostics' subsidiary and the opportunity to advance the Company's Diagnostic program". Duyuru • Mar 20
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 09, 2025 Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 09, 2025. Duyuru • Mar 14
Shuttle Pharmaceuticals Provides Update Regarding Minimum Equity Requirement of Nasdaq As disclosed previously, on September 10, 2024, Shuttle Pharmaceuticals Holdings, Inc. received a written notice from The Nasdaq Stock Market LLC notifying the Company that it was no longer in compliance with Nasdaq Rule 5550(b)(1), the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq. In response to the Notice, the Company submitted its plan of regain compliance to Nasdaq (the “Plan”) and on November 26, 2024, the Company received notice from Nasdaq that it had accepted the Plan. In accordance with the Plan, the Company is required to complete an equity offering sufficient to bring the Company’s stockholders’ equity above the Minimum Equity Requirement and be able to demonstrate that it is in compliance in its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On March 13, 2025, following the Company’s receipt of approximately $5.2 million in net proceeds from the Offering, the Company believes it is now in compliance with the Minimum Equity Requirement and will be able to demonstrate such compliance in its First Quarter Form 10-Q. Nasdaq will continue to monitor the Company’s ongoing compliance with the Minimum Equity Requirement and, if at the time of the filing of its First Quarter Form 10-Q the Company does not evidence compliance, it may be subject to delisting. Duyuru • Mar 13
Shuttle Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5.732174 million. Shuttle Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5.732174 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,340,921
Price\Range: $0.3
Discount Per Security: $0.012
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 17,825,746
Price\Range: $0.299
Discount Per Security: $0.012 Duyuru • Mar 12
Shuttle Pharmaceuticals Holdings, Inc. Appoints Christopher Cooper as Interim Co-CEO Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company’s capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company’s Board of Directors, will continue in his role as Co-CEO overseeing the Company’s scientific and clinical trial activities. Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University. Duyuru • Feb 13
Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering. Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant New Risk • Nov 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 83% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$1.3m). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.12m market cap). Duyuru • Nov 26
Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient Shuttle Pharmaceuticals Holdings, Inc. announced first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA is one of six cancer centers conducting the clinical trials. Shuttle Pharma previously announced the dosing of patients at Miami Cancer Institute, part of Baptist Health South Florida. The Phase 2 trial will consist initially of 40 patients randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients to the trial at the optimal dose allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Phase 2 clinical trial will be conducted on the most aggressive brain tumors out there – IDH wild-type, methylation negative glioblastoma patients. This cohort of patients currently only have radiation as the standard of care, with more than half of the patients surviving for less than 12 months after diagnosis. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for treatment of the disease. In addition to UVA Cancer Center, the Phase 2 trial is currently being conducted at Georgetown University Medical Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida. New Risk • Nov 15
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$1.3m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$1.3m). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$2.38m market cap). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding). Duyuru • Oct 18
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in funding Shuttle Pharmaceuticals Holdings, Inc. entering into securities purchase agreements with a small group of accredited investors to issue 5% original issue discount senior secured convertible note and warrant offering for gross proceeds $1.3million on October 17, 2024. The Notes mature one year from the date of issuance, accrue interest at the rate of 14.5% per annum, and are convertible at a 110% premium at any time beginning three months after the date of issuance. Duyuru • Sep 20
Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering. Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Security Name: Common Warrants
Security Type: Equity Warrant Duyuru • Sep 16
Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease. The Phase 2 clinical trial will enroll patients with the most aggressive brain tumors out there – IDH wild-type, methylation negative glioblastoma. Presently, radiation is the only approved standard of care for this particular group of patients, with more than half of the patients surviving for less than 12 months after diagnosis. Shuttle Pharma’s Phase 2 clinical trial will consist initially of 40 patients randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients on the optimal dosage allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Company expects the trial to be completed over a period of 18 to 24 months. Duyuru • Sep 14
Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement On September 10, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the Company"), received a letter (the Notification") from The Nasdaq Capital Market (Nasdaq"), dated September 10, 2024, notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders' equity of at least $2,500,000. In the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2024, the Company reported stockholders' equity of $801,434, which is below the minimum stockholders' equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). In addition, presently, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. This Notification has no immediate effect on the listing of the Company's securities on the Nasdaq Capital Market. Nasdaq has provided the Company with 45 calendar days, or until October 25, 2024, to submit a plan to regain compliance with the minimum stockholders' equity standard. If the Company's plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from September 10, 2024 for the Company to regain compliance. The Company is presently evaluating various courses of action to regain compliance and intends to timely submit a compliance plan to Nasdaq. However, there can be no assurance that the Company's plan will be accepted or that, if it is, the Company will be able to regain compliance and maintain its listing on the Nasdaq Capital Market. If the Company's plan to regain compliance is not accepted or if Nasdaq does not grant an extension and the Company does not regain compliance by October 25, 2024, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company's securities will become subject to delisting. In that event, the Company will have an opportunity to appeal Nasdaq's decision to a hearings panel. Duyuru • Sep 05
Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c) Shuttle Pharmaceuticals Holdings, Inc. provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024. Due to the recent SEC sanctions against B.F. Borgers, CPA, PC, an auditor previously engaged by Shuttle Pharma, a re-audit of prior years’ financial statements has been required and was performed by Shuttle Pharma’s current auditors, Forvis Mazars, LLP. This re-audit caused a delay in filing the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the ‘Q2 Quarterly Report’). As a result, on August 21, 2024, Shuttle Pharma received notice from the Nasdaq Stock Exchange, LLC that it had fallen out of compliance with Nasdaq’s Listing Rule 5250(c) for not timely filing the Second Quarter Quarterly Report. As of today’s date, Shuttle Pharma has now filed its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, including the re-audited information, as well as its Quarterly Report on Form 10-Q/A for the period ended March 31, 2024 and the Second Quarter Quarterly Report. Following these filings, Shuttle Pharma has now regained compliance with Listing Rule 5250(c). Duyuru • Aug 29
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Shuttle Pharmaceuticals Holdings, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule. Nasdaq sent notice to the Company that it had regained compliance as of August 27, 2024, after it traded above $1.00 per share for ten consecutive trading days. Duyuru • Aug 28
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) Shuttle Pharmaceuticals Holdings, Inc. reported that it received formal notice (the ‘Notice’) from the Nasdaq Stock Market LLC (‘Nasdaq’) that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the ‘Listing Rule’) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the ‘Q2 Quarterly Report’). The Company's non-compliance with the Listing Rule resulted from the Company's re-audit of its financial statements for the year ended December 31, 2022, which, as previously disclosed, arose following the SEC's imposition of sanctions against B.F. Borgers CPA, PC, the Company's auditor for the 2022 fiscal year. Following the SEC sanctions, the Company's current auditor, Forvis Mazars, LLP (‘Forvis’), began the process of re-auditing the Company's 2022 financial statements and the Company is now preparing an amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and an amended Quarterly Report on Form 10-Q for the period ended March 31, 2024, each of which will include re-stated financial information resulting from the re-statement of the Company's 2022 financial statements. The Company anticipates these reports will be filed in the next several days, after which time the Company will be in a position to file the Second Quarter Quarterly Report to automatically regain compliance with the Listing Rule. Should the Company require additional time to file the Second Quarter Quarterly Report, Nasdaq rules require the Company to submit a proposed plan of compliance to Nasdaq within 60 days of receipt of the Notice and could then receive up to 180 days to regain compliance with the Listing Rule. The Nasdaq Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. Duyuru • Aug 15
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease. The Phase 2 clinical trial will be conducted on patients with the most aggressive brain tumors out there – IDH wild-type, methylation negative glioblastoma. Presently, radiation is the only approved standard of care for this particular group of patients, with more than half of the patients surviving for less than 12 months after diagnosis. Shuttle Pharma’s Phase 2 clinical trial will consist initially of 40 patients randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients on the optimal dosage allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Company expects the trial to be completed over a period of 18 to 24 months. Shuttle Pharma expects the Phase 2 clinical trial will be carried out at six site locations, with all sites anticipated to be treating patients in the coming months. Duyuru • Aug 14
Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing On 08/13/2024, Shuttle Pharmaceuticals Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Jul 20
Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303 Shuttle Pharmaceuticals Holdings, Inc. announced the publication of a manuscript reporting on the ability of one of the Company’s HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression
resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth,” reports the work of Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Scott Grindrod, Shuttle Pharma’s Principal Scientist, and was published in PLOS ONE, a peer-reviewed open access journal published by the Public Library of Science (PLOS). SP-1-303, initially discovered and synthesized in Shuttle Pharma’s laboratories by Dr. Grindrod, is one of the Company’s pre-clinical selective Class I HDAC inhibitors. Histone deacetylase inhibitors sensitize cancers to the effects of radiation, protect normal tissues from radiation injury and activate the immune system. SP-1-303
is a selective Class I HDAC inhibitor that inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER + BC. Furthermore, SP-1-303 increases the PD-L1 expression level in a time-dependent manner, supporting combination of SP-1-303 with an immune checkpoint blocker to enhance the therapeutic benefits. Duyuru • Jun 18
Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company’s current Chief Financial Officer, Michael Vander Hoek, who also serves as Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis. Mr. Lorber is a CPA with more than 40 years of professional finance experience, including 15 years with Legg Mason, Inc. ("Legg Mason”), one of the world’s larger public global asset management firms where he served as a Managing Director and Chief Accounting Officer until its sale in 2020. More recently, Mr. Lorber has served in leadership roles with several privately held businesses, overseeing finance, IT and HR functions. Prior to Legg Mason, Mr. Lorber served as Internal Audit Director of Freddie Mac and has also worked for several international public accounting firms. Mr. Lorber will initially serve as the Company’s part-time Chief Financial Officer until September 9, and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company. Mr. Vander Hoek will become the full-time Vice President, Regulatory concurrent with Mr. Lorber’s full-time appointment as Chief Financial Officer. Duyuru • Jun 13
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024 Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024. New Risk • May 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.5m free cash flow). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$6.95m market cap). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding). New Risk • Mar 24
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.6m free cash flow). Earnings have declined by 36% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$7.20m market cap). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 36% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.32m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Duyuru • Jan 08
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence the Phase II study. Shuttle Pharma is currently finalizing site enrollment with 'first patient, first dose' expected in the coming months. Ropidoxuridine is Shuttle Pharma's lead radiation sensitizer candidate for use in combination with radiation therapy (RT) to treat glioblastoma, a deadly malignancy of the brain with no known cure. An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years. Shuttle Pharma has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease. Duyuru • Dec 11
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the next phase of development of Ropidoxuridine. Ropidoxuridine is Shuttle Pharma's lead radiation sensitizer candidate for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Ropidoxurine is Shuttle Pharma's lead radiation Sensitizer candidate for use in combined with radiation therapy (RT) To treat brain tumors (gliOBlastoma), a deadly malignedancy of the brain with noknown cure. RT is a proven modality for treating cancers. However, there is a significant need in the market to make radiation more effective. By developing radiation sensitizers, Shuttle Pharma aims to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination with surgery, chemotherapy and immunotherapy. An IND submission is a request submitted to the regulatory authorities seeking permission to test a new drug or therapeutic substance in humans. The submission includes detailed information about the drug, its composition, pharmacology, toxicology data from preclinical studies, proposed clinical trial protocols, and information on manufacturing and quality control. With the IND application submission now complete, the FDA is expected to provide Shuttle Pharma with its decision to proceed with the Phase II trial within approximately 30 days. The submission of the IND follows recent receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application (PIND) meeting with the FDA in September 2023. During the PIND meeting, the FDA provided positive feedback and guidance on the Company's Chemistry, Manufacturing, and Controls (CMC) and clinical protocol design for Ropidoxuridine, thus providing the pathway to this IND submission. The planned Phase II trial will investigate whether a new treatment, Ropidoxuridine., taken during radiation treatment, will be a safe and possibly effective for treatment of patients with newly diagnosed IDH- wildtype glioblastoma with unmethylated MGMT promoter. An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years. Shuttle Pharma has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease. New Risk • Oct 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.7m free cash flow). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$7.83m market cap). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (34% increase in shares outstanding). Duyuru • Oct 22
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023 Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023, at 12:00 US Eastern Standard Time. Agenda: To consider and elect six Directors named in the attached Proxy Statement to serve until the 2024 Annual Meeting of  FOR each director nominee Stockholders; to consider and ratify appointment of FORVIS LLP as the Company's independent auditor for the fiscal year ending a for December 31, 2023; to consider and approve the Company's executive compensation; and to consider other business matters. Duyuru • Sep 26
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application (PIND) meeting with the U.S. Food and Drug Administration (FDA). The FDA's positive feedback and guidance on the Company's Chemistry, Manufacturing, and Controls (CMC) and clinical protocol design for Ropidoxuridine provides a pathway to IND application submission in the fourth quarter of 2023 to initiate the Phase 2 clinical trial. Ropidoxuridine (IPdR) is Shuttle's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease. Duyuru • Sep 12
Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform Shuttle Pharmaceuticals Holdings, Inc. announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled "Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof." The company's HDAC pre-clinical inhibitor platform includes: SP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6. SP-2-225 has effects on the regulation of the immune system. The interactions of radiation therapy with the immune response to cancers are of great current interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. For this reason, Shuttle Pharma selected SP-2-225 as the candidate lead HDAC inhibitor for preclinical development. Shuttle Pharma is advancing drug manufacture and IND-enabling studies with the goal of enabling a Phase I clinical trial in 2024. With the introduction of check-point inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response following RT continues to be of significant clinical and commercial interest. SP-1-161 is Shuttle Pharma's pre-clinical candidate lead HDAC inhibitor, radiation sensitizing candidate product. This pan HDAC inhibitor initiates the mutated ataxia-telangiectasia response pathway. Using rational drug design, Shuttle Pharma discovered HDAC inhibitors and ATM activators capable of radiation sensitizing cancer cells and protecting normal cells. The candidate drug may serve as a direct chemotherapeutic agent or as a radiation sensitizer for treating cancers. In preclinical studies, SP-1-161 protected normal breast epithelial cells (184A1) following exposure to ionizing radiation while increasing sensitivity of breast cancer cells (MCF7). SP-1-161 provides this dual function in a single molecule and this molecule is differentiated from other HDAC inhibitors by treatment of cancers while protecting normal cells. SP-1-303 is Shuttle Pharma's pre-clinical selective Class I HDAC inhibitor that preferentially affects histone deacetylases HDAC1 and HDAC3 and is a member of the Class I HDAC family. SP-1-303 data show direct cellular toxicity in estrogen receptor (ER) positive breast cancer cells. Duyuru • Sep 08
Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement On August 31, 2023, Shuttle Pharmaceuticals Holdings, Inc. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (‘Nasdaq’) stating that for the 30 consecutive business day period between July 20, 2023 to August 30, 2023 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until February 27, 2024 (the ‘Compliance Period’), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive trading days, unless such period is extended by Nasdaq. If the Company does not regain compliance with the Minimum Bid Price Requirement by February 27, 2024, the Company may be eligible for an additional 180-day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company cannot regain compliance during the Compliance Period or any subsequently granted compliance period, Nasdaq will provide the Company with notice that its common stock will be subject to delisting. At that time, the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearings Panel. Nasdaq’s notice to the Company of noncompliance has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on The Nasdaq Capital Market under the symbol ‘SHPH.’ There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or maintain compliance with any of the other Nasdaq continued listing requirements. The Company will continue to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement. New Risk • Aug 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.7m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$12.1m market cap). Duyuru • May 29
Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing Rules On May 24, 2023, Shuttle Pharmaceuticals Holdings, Inc. received notice from the Nasdaq Stock Market, LLC (‘Nasdaq’) that the company have fallen out of compliance with the Nasdaq Listing Rules for continued listing as a result of being unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the ‘Form 10-Q’) within the five day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. The company’s Form 10-Q had not been timely filed as a result of certain accounting complexities that arose in relation to the company’s convertible note held by Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B. Following receipt of notice from Nasdaq, the company informed Nasdaq of plan to file Form 10-Q on or about May 25, 2023, which would allow the company to regain compliance with Nasdaq Listing Rules. On May 25, 2023, the company filed Form 10-Q with the Securities and Exchange Commission and, as a result, the company has now regained compliance with the Nasdaq Listing Rules. Duyuru • May 16
Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing On 05/15/2023, Shuttle Pharmaceuticals Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Jan 13
Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLC Shuttle Pharmaceuticals Holdings, Inc. announced that it has entered into a security purchase agreement with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, a fund managed by Ayrton Capital LLC for private placement of Senior Secured Convertible Note for gross proceeds of $4,000,000 on January 11, 2023. The company will also issue approximately 1.018 million warrants at an exercise price of $2.35 per share. The convertible note is repayable over 26 months and bears interest at the rate of 5% per annum. the convertible note is convertible into shares of common stock at price per share equal to the lower of $2.35, 90% of the three lowest daily VWAPs of the 15 trading days prior to the payment date or 90% of the VWAP of the trading day prior to payment date. Duyuru • Jan 12
Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for Cancer Shuttle Pharmaceuticals Holdings, Inc. announced the publication of a manuscript discussing immune responses taking place in patients after radiation therapy for cancer. The manuscript, titled, "Radiation therapy induces innate immune responses in patients treated for prostate cancer. Radiation therapy (RT) is a curative therapeutic modality used to treat cancers as a single agent or in combination with surgery and chemotherapy. To understand systemic clinical responses after radiation exposure, proteomic and metabolomic analyses were performed on plasma obtained from cancer patients at intervals after prostate radiation therapy. DNA Damage Response (DDR) increased within the first hour after treatment and returned to baseline by one month. Robust immune signaling also increased within one hour of treatment but persisted for up to three months thereafter. The data support innate immune activation as a critical clinical response of patients receiving radiation therapy for prostate cancer, potentially informing multidisciplinary therapeutic strategies for cancer treatment. The study was supported by NIH SBIR Contracts to Shuttle Pharmaceuticals, Inc. which were subcontracted from Shuttle Pharmaceuticals, Inc. to Georgetown University. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Bette Jacobs was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Nov 02
Shuttle Pharmaceuticals Holdings, Inc. Appoints Bette Jacobs to Its Board of Directors Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director. Dr. Jacobs will serve on the Audit Committee and the Nominating and Corporate Governance Committee. Dr. Jacobs is a professor in the department of health systems administration at Georgetown University and a distinguished scholar at the O'Neill Institute for National and Global Health Law. She is noted for transdisciplinary and cross-sector work in system design. A voting member of the Cherokee Nation, Dr. Jacobs has lifetime involvement in advancing equity and diversity programs. Previously, Dr. Jacobs was dean at the Georgetown University School of Nursing and Health Studies, vice president for Honda of America Manufacturing, founding faculty and associate director of applied research at UAB Civitan International Research Center, and acting dean of graduate studies and research at California State University. She has been a fellow and visiting professor at the University of Oxford Campion Hall and an academic guest scholar and lecturer for Chang Gung University, Anhui University, Tokyo Medical and Dental University, University of British Columbia, University of Sienna, Sciences Po, and the Karolinska Institute. In addition to serving on several start-up boards, Dr. Jacobs also founded the National Coalition of Ethnic Minority Nurse Associations funded by the NIH National Institute of General Medical Sciences. Dr. Jacobs' current projects focus on faith-based health systems; decolonization and ecology; migration, indigeneity, and gender; missing and murdered people; and international indigenous rights. Dr. Jacobs earned her B.S. and M.S. from California State University and holds a Ph.D. from the University of Texas. Duyuru • Sep 16
Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer Treatment Shuttle Pharmaceuticals Holdings, Inc. announced that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy. Various sources have estimated that more than 800,000 patients in the US are treated with radiation therapy for their cancers. According to the American Cancer Society about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes. The number of patients being treated with RT is expected to grow by more than 22% over the next five years. Based on a rough estimate of a course of radiation sensitizing brand drug therapy (used off label at this time) of $12,000 per patient--the market size would be in excess of $4.0 billion annually. Duyuru • Sep 01
Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million. Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 1,225,888
Price\Range: $8.125
Discount Per Security: $0.568